Methylene blue is a dye and medication that most people encounter in one of two ways. It is given intravenously as a prescription product, sold under the brand name ProvayBlue, to treat methemoglobinemia, a blood disorder that limits oxygen delivery. It is also taken informally in low oral doses, outside any approved by FDA indication, by people who use it as a nootropic or general wellness supplement. Neither use puts a person at risk of a positive result on a standard employment or clinical drug test, because methylene blue is not a controlled substance and it is not one of the analytes any routine panel is built to detect.
What methylene blue does reliably is turn urine a visible blue or blue green color. That color change does not register on a drug test screen, but it can catch the attention of a specimen collector and may prompt a specimen validity check at the laboratory. This article explains the difference between what a panel screens for, what the dye actually does to a urine sample, and what a collector or laboratory is required to do when a specimen looks unusual.
What methylene blue is and why people use it
Methylene blue (methylthioninium chloride) is the active ingredient in ProvayBlue, an injectable product approved for acquired methemoglobinemia. The prescribing information on file with the National Library of Medicine's DailyMed service describes it as a blue dye that passes largely unchanged into the urine. Roughly 40 percent of a dose is excreted in urine without being metabolized, which is the direct reason urine color changes after a dose.
Outside the prescription setting, some people take low dose oral methylene blue, sometimes compounded or sold as a research chemical, for purposes that are not reviewed or approved by the Food and Drug Administration. This article does not endorse or provide dosing guidance for that use. Anyone taking methylene blue by prescription or otherwise should keep documentation of the product and, if a workplace or clinical test is involved, be prepared to discuss it with the laboratory's medical review officer rather than the collector.
Is methylene blue included on a drug test panel?
No. Standard urine, oral fluid, and blood drug screens are built around specific analyte classes: marijuana metabolites (THC), cocaine metabolites, opiates, amphetamines and methamphetamine, phencyclidine (PCP), and in expanded panels benzodiazepines, barbiturates, and synthetic opioids. Methylene blue is chemically unrelated to every one of those classes. There is no published cross reactivity data showing that methylene blue triggers a positive immunoassay screen on any of them, and confirmation testing by gas chromatography or liquid chromatography with mass spectrometry (GC/MS or LC/MS) is not looking for methylene blue in the first place, because it is not a substance any employer panel is designed to find.
| Screening panel class | What it targets | Does methylene blue cross react? |
|---|---|---|
| THC (marijuana metabolites) | 11-nor-9-carboxy-THC | No credible cross reactivity reported |
| Opiates | Morphine, codeine and related metabolites | No credible cross reactivity reported |
| Amphetamines | Amphetamine, methamphetamine | No credible cross reactivity reported |
| Cocaine metabolites | Benzoylecgonine | No credible cross reactivity reported |
| PCP | Phencyclidine | No credible cross reactivity reported |
| Benzodiazepines | Diazepam, oxazepam and related metabolites | No credible cross reactivity reported |
If a published case report or peer reviewed study later documents a specific cross reactivity, that would be the kind of finding that belongs on a product insert or a laboratory bulletin. Until a laboratory or the manufacturer documents one, the honest answer for every panel class above is that there is no credible evidence of interference with the immunoassay screen itself.
Why the urine turns blue and what that means for a specimen
The interference that does exist is not with the drug analyte screen. It is with the physical appearance of the specimen and, potentially, with other colorimetric tests that rely on a color change to report a result. The ProvayBlue prescribing information states directly that the product is a blue dye that passes freely into the urine and may interfere with the interpretation of any urine test that relies on a blue color indicator, giving the example of a dipstick test for leucocyte esterase. That same principle, a strong background dye masking or altering a color based readout, is why a collector who sees unmistakably blue or blue green urine is trained to look twice.
A rapid onsite immunoassay cup or dip card is read by color change at a test line. A heavily dyed specimen does not change the chemistry of the screen, but it can make a weak line harder to read by eye, which is one more reason laboratories prefer to confirm anything borderline with instrumented testing rather than relying on a visual read alone.
What a collector is required to check
Federal workplace testing under 49 CFR Part 40 gives collectors a specific duty to inspect every specimen. Under 49 CFR 40.65, the collector must inspect the specimen for unusual color, the presence of foreign material, or other signs of tampering as soon as it is handed over. Unusual color by itself is not treated as proof of cheating. It is a prompt for the collector to document what was observed and, depending on the circumstances, for the laboratory to run specimen validity testing.
Specimen validity testing is a defined part of the federal testing process. Under 49 CFR 40.91, a laboratory may conduct validity testing on any specimen that exhibits abnormal physical characteristics, such as an unusual color or odor, or that reacts unexpectedly during initial or confirmatory testing. Validity testing looks at pH, creatinine, specific gravity, and the presence of oxidizing adulterants. A blue tinted specimen that otherwise falls within normal pH, creatinine, and specific gravity ranges is not treated as substituted or adulterated just because of its color. The color is a trigger for a closer look, not a conclusion.
The Substance Abuse and Mental Health Services Administration oversees the Mandatory Guidelines that federal workplace drug testing programs and HHS certified laboratories follow, including the standards that specimen validity testing is built on. Employers running non federal programs often model their own collection and validity procedures on the same framework, even when Part 40 itself does not apply to their workforce.
What to do if you take methylene blue and face a test
The practical answer is documentation, not avoidance. Anyone on a prescribed methylene blue product should keep the prescription or the treating provider's information available. If a collector notes unusual color, that note goes into the chain of custody paperwork along with any explanation offered. From there, the laboratory's medical review officer (MRO) is the person who reviews a nonnegative or flagged result in context of prescriptions and medical history before any result is reported to an employer. A specimen that is unusually colored but otherwise valid on laboratory testing does not, by itself, become a positive or a refusal.
This process exists specifically so that a legitimate prescription does not get treated the same way as an attempt to defeat a test. It is also why collection staff should never be asked to interpret color changes on their own; that judgment call belongs to the laboratory and the MRO, working from validity testing results and documentation, not from a visual impression at the collection site.
Serotonin syndrome: a safety note, not medical advice
This is worth flagging for anyone managing a drug testing program or reviewing an employee's medication list, though it has nothing to do with test results. The ProvayBlue label carries a boxed warning, the strongest warning the FDA requires on a drug label, for serotonin syndrome when methylene blue is combined with serotonergic medications such as SSRIs, SNRIs, or MAOIs, or with opioids. That is a medical interaction question between a patient and their prescriber, not a drug testing question, and nothing in this article should be read as dosing or treatment guidance. Anyone with questions about combining methylene blue with another medication should raise it with the prescribing clinician, not with a testing program.
How this fits into a broader screening and confirmation program
None of this changes how a employer or clinic should run its testing program. A rapid cup or dip card screen is a first pass against defined analyte classes. Anything presumptive positive, and anything with an unusual specimen appearance, should route to confirmation by GC/MS or LC/MS at a certified laboratory, with an MRO reviewing the final result against prescription documentation. Methylene blue does not change any analyte result, but a visibly blue specimen is still worth noting on the chain of custody form so the laboratory has context if validity testing is triggered.
Programs that want a closer look at how laboratories distinguish color from chemistry can review how specimen validity testing works in general, and how collectors read color on a cup, in the related articles below. American Screening Corporation's wholesale portal at wholesale.americanscreeningcorp.com and its drug test cup collection carry the collection devices and confirmation referral services that support this kind of program.
Frequently asked questions
Does methylene blue cause a false positive on a drug test?
There is no credible published evidence that methylene blue cross reacts with the immunoassay screens used for THC, opiates, amphetamines, cocaine, PCP, or benzodiazepines. It is not chemically related to any of those drug classes.
Why does my urine turn blue after taking methylene blue?
Methylene blue is a dye that is excreted largely unchanged in urine. The DailyMed prescribing information for ProvayBlue confirms that a meaningful portion of the dose passes into the urine, which produces the blue or blue green color.
Will a blue colored specimen be rejected by a collector?
Not automatically. Under 49 CFR 40.65 the collector documents unusual color as part of the standard inspection, and under 49 CFR 40.91 the laboratory may run specimen validity testing in response. Color alone is not proof of tampering.
Does methylene blue show up on a laboratory confirmation test?
Standard GC/MS or LC/MS confirmation panels are built to detect specific drug classes and their metabolites. Methylene blue is not one of the analytes those confirmation panels are designed to report.
Should I tell the collector I am taking methylene blue?
Documentation generally goes through the medical review officer process rather than the collector. Keeping a prescription or provider note available, and disclosing it when asked about medications, supports an accurate MRO review if the specimen's appearance is questioned.
Is methylene blue a controlled substance?
No. Methylene blue is not scheduled as a controlled substance, which is part of why it is not included as a target analyte on standard drug test panels.
Related reading: Specimen Validity Testing Explained and What Do the Colors Mean on a Drug Test Cup.
This article is general information, not medical or legal advice. Consult a qualified clinician about any medication question and a medical review officer or counsel about any specific testing decision.
